


Amendments to the Claims:

This listing of claims will replace all prior versions,  
and listings, of claims in the application:

Listing of Claims:


1-26 (Cancelled).

27 (Withdrawn). A cell activator comprising a  
glycosphingolipid having a structure represented by the  
following formula (1)  
formula (1)



wherein R<sup>1</sup> represents the following formula (1-1):

formula (1-1)




wherein  $R^3$  represents alkyl or alkenyl and  $R^4$  represents alkyl;  
and

$R^2$  represents hydrogen, or  $\alpha$ -galactose,  $\alpha$ -glucose,  
 $\alpha$ -mannose,  $\alpha$ -glucosamine,  $\beta$ -glucosamine or a combination  
thereof.


28 (Withdrawn). A cell activator comprising a  
glycosphingolipid having a structure represented by the  
following formula (3):

formula (3)




wherein  $R^5$  represents  $R^{51}$ ,  $R^{52}$ ,  $R^{53}$ ,  $R^{54}$ ,  $R^{55}$ ,  $R^{56}$ ,  $R^{57}$ ,  
 $R^{58}$ ,  $R^{59}$ ,  $R^{70}$ ,  $R^{71}$ ,  $R^{72}$ ,  $R^{73}$ ,  $R^{74}$ ,  $R^{75}$ ,  $R^{76}$ ,  $R^{77}$ , or  $R^{78}$ ; and  $R^6$   
represents hydrogen,  $R^{62}$ ,  $R^{63}$ ,  $R^{64}$ , or  $R^{65}$ :


R<sup>51</sup> :




R<sup>52</sup> :




R<sup>53</sup> :




R<sup>54</sup> :




R<sup>55</sup> :




R<sup>56</sup> :




R<sup>57</sup> :




R<sup>58</sup> :




R<sup>59</sup> :




R<sup>70</sup> :




R<sup>71</sup> :




R<sup>72</sup> :




R<sup>73</sup> :




R<sup>74</sup> :




R<sup>75</sup> :




R<sup>76</sup>:




R<sup>77</sup>:




R<sup>78</sup>:




R<sup>62</sup>:




R<sup>64</sup>:



R<sup>63</sup>:



R<sup>65</sup>:



29 (Withdrawn). A method of activating NKT cell which comprises administering the cell activator according to claim 27 to a mammal.

30 (Withdrawn). A method of activating NKT cell which comprises administering the cell activator according to claim 28 to a mammal,

31 (Withdrawn). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 27 to a mammal.

32 (Withdrawn). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 28 to a mammal.

33 (Withdrawn). A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 27 to a mammal.

34 (Withdrawn). A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 28 to a mammal.

35 (Withdrawn). A method of activating dendritic cell which comprises administering the cell activator according to claim 27 to a mammal.

36 (Withdrawn). A method of activating dendritic cell which comprises administering the cell activator to claim 28 to a mammal.

37 (Withdrawn). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 27 to a mammal.

38 (Withdrawn). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (Withdrawn). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 27 to a mammal.

40 (Withdrawn). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.



41 (Withdrawn). A method of activating NK cell which comprises administering the cell activator according to claim 27 to a mammal.

42 (Withdrawn). A method of activating NK cell which comprises administering the cell activator according to claim 28 to a mammal.

43 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 27 to a mammal.

44 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 27 to a mammal.

46 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 27 to a mammal.

48 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (Previously Presented). A method of inhibiting viral activity which comprises administering the cell according to claim 27 to a mammal.

50 (Previously Presented). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (Withdrawn). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 27 to a mammal.

52 (Withdrawn). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (Withdrawn). A method of accelerating NO production which comprises administering the cell activator according to claim 27 to a mammal.

54 (Withdrawn). A method of accelerating NO production which comprises administering the cell activator according to claim 28 to a mammal.

55 (New). A method of inhibiting viral activity of which comprises administering the cell activator according to claim 28 to a mammal, wherein R<sup>6</sup> represents hydrogen.

56 (New). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal, wherein R<sup>5</sup> represents R<sup>51</sup>, R<sup>52</sup>, R<sup>53</sup>, R<sup>54</sup>, R<sup>55</sup>, and R<sup>56</sup>.